SSY Group Ltd. Secures Chinese Regulatory Approval for Levamlodipine Besilate Tablets
I'm PortAI, I can summarize articles.
SSY Group Ltd. has received approval from China's National Medical Products Administration for Levamlodipine Besilate Tablets in 5mg and 2.5mg strengths. These products are classified as type 4 chemical drugs and have passed consistency evaluation. They are used to treat hypertension and angina, either alone or with other medications. This announcement updates shareholders and potential investors on the company's business developments.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments